Cargando…

Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy

Atherosclerosis (AS) is a leading cause of vascular diseases that severely threats the human health due to the lack of efficient therapeutic methods. During the development and progress of AS, macrophages play critical roles, which are polarized into pro-inflammatory M1 phenotype to excrete abundant...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Weidong, Xu, Yiyan, Yao, Ye, Yue, Jie, Wu, Zhen, Li, Haocheng, Shen, Guanghui, Liao, Yan, Wang, Haiyang, Zhou, Wenhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858544/
https://www.ncbi.nlm.nih.gov/pubmed/35183183
http://dx.doi.org/10.1186/s12951-022-01296-x
_version_ 1784654264047501312
author Sun, Weidong
Xu, Yiyan
Yao, Ye
Yue, Jie
Wu, Zhen
Li, Haocheng
Shen, Guanghui
Liao, Yan
Wang, Haiyang
Zhou, Wenhu
author_facet Sun, Weidong
Xu, Yiyan
Yao, Ye
Yue, Jie
Wu, Zhen
Li, Haocheng
Shen, Guanghui
Liao, Yan
Wang, Haiyang
Zhou, Wenhu
author_sort Sun, Weidong
collection PubMed
description Atherosclerosis (AS) is a leading cause of vascular diseases that severely threats the human health due to the lack of efficient therapeutic methods. During the development and progress of AS, macrophages play critical roles, which are polarized into pro-inflammatory M1 phenotype to excrete abundant cytokines and overproduce reactive oxygen species (ROS), and take up excess amount of lipid to form foam cells. In this work, we developed a MnO(2)-based nanomedicine to re-educate macrophages for targeting AS therapy. The MnO(2) was one-pot synthesized under mild condition, showing intrinsic catalase-mimic activity for self-oxygenation by using endogenous H(2)O(2) as substrate. Moreover, the mesoporous structure as well as the abundant metal coordination sites in MnO(2) structure facilitated the loading of an anti-AS drug of curcumin (Cur), achieving extraordinarily high drug loading capacity of 54%. Cur displayed a broad spectrum of anti-oxidant and anti-inflammatory capabilities to repolarize M1 macrophages into M2 phenotype, and the catalytic MnO(2) recovered the function of lipid efflux transporter to remove lipid from cells by suppressing HIF-1α. Collectively, the nanocarrier and the payload drug functioned as an all-active nanoplatform to synergistically alleviate the syndromes of AS. In ApoE−/− mice model, the nanosystem could significantly prolong the circulation half-life of Cur by sixfold, and enhance drug accumulation in atherosclerotic lesion by 3.5-fold after intravenous injection by virtue of surface hyaluronic acid (HA) modification. As a result, a robust anti-AS efficacy was achieved as evidenced by the decrease of atherosclerotic lesion, plaque area, lipid level. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01296-x.
format Online
Article
Text
id pubmed-8858544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88585442022-02-23 Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy Sun, Weidong Xu, Yiyan Yao, Ye Yue, Jie Wu, Zhen Li, Haocheng Shen, Guanghui Liao, Yan Wang, Haiyang Zhou, Wenhu J Nanobiotechnology Research Atherosclerosis (AS) is a leading cause of vascular diseases that severely threats the human health due to the lack of efficient therapeutic methods. During the development and progress of AS, macrophages play critical roles, which are polarized into pro-inflammatory M1 phenotype to excrete abundant cytokines and overproduce reactive oxygen species (ROS), and take up excess amount of lipid to form foam cells. In this work, we developed a MnO(2)-based nanomedicine to re-educate macrophages for targeting AS therapy. The MnO(2) was one-pot synthesized under mild condition, showing intrinsic catalase-mimic activity for self-oxygenation by using endogenous H(2)O(2) as substrate. Moreover, the mesoporous structure as well as the abundant metal coordination sites in MnO(2) structure facilitated the loading of an anti-AS drug of curcumin (Cur), achieving extraordinarily high drug loading capacity of 54%. Cur displayed a broad spectrum of anti-oxidant and anti-inflammatory capabilities to repolarize M1 macrophages into M2 phenotype, and the catalytic MnO(2) recovered the function of lipid efflux transporter to remove lipid from cells by suppressing HIF-1α. Collectively, the nanocarrier and the payload drug functioned as an all-active nanoplatform to synergistically alleviate the syndromes of AS. In ApoE−/− mice model, the nanosystem could significantly prolong the circulation half-life of Cur by sixfold, and enhance drug accumulation in atherosclerotic lesion by 3.5-fold after intravenous injection by virtue of surface hyaluronic acid (HA) modification. As a result, a robust anti-AS efficacy was achieved as evidenced by the decrease of atherosclerotic lesion, plaque area, lipid level. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01296-x. BioMed Central 2022-02-19 /pmc/articles/PMC8858544/ /pubmed/35183183 http://dx.doi.org/10.1186/s12951-022-01296-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Weidong
Xu, Yiyan
Yao, Ye
Yue, Jie
Wu, Zhen
Li, Haocheng
Shen, Guanghui
Liao, Yan
Wang, Haiyang
Zhou, Wenhu
Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
title Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
title_full Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
title_fullStr Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
title_full_unstemmed Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
title_short Self-oxygenation mesoporous MnO(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
title_sort self-oxygenation mesoporous mno(2) nanoparticles with ultra-high drug loading capacity for targeted arteriosclerosis therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858544/
https://www.ncbi.nlm.nih.gov/pubmed/35183183
http://dx.doi.org/10.1186/s12951-022-01296-x
work_keys_str_mv AT sunweidong selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT xuyiyan selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT yaoye selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT yuejie selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT wuzhen selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT lihaocheng selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT shenguanghui selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT liaoyan selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT wanghaiyang selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy
AT zhouwenhu selfoxygenationmesoporousmno2nanoparticleswithultrahighdrugloadingcapacityfortargetedarteriosclerosistherapy